TY - JOUR
T1 - Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery
AU - Kasuya, Takeshi
AU - Jung, Joohee
AU - Kinoshita, Rie
AU - Goh, Yasumasa
AU - Matsuzaki, Takashi
AU - Iijima, Masumi
AU - Yoshimoto, Nobuo
AU - Tanizawa, Katsuyuki
AU - Kuroda, Shun'ichi
N1 - Funding Information:
The authors thank Professor M. Seno (Okayama University), Professor A. Kondo (Kobe University), and Professor M. Ueda (Keio University) for their helpful advice. We are grateful to Ms. Y. Matsushita, Ms. N. Shikaku, and Ms. Y. Matsui for their technical support. This work was supported in part by the Regional Research and Development Resources Utilization Program from the Japan Science and Technology Agency.
PY - 2009
Y1 - 2009
N2 - A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.
AB - A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.
UR - http://www.scopus.com/inward/record.url?scp=71549162528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71549162528&partnerID=8YFLogxK
U2 - 10.1016/S0076-6879(09)64008-8
DO - 10.1016/S0076-6879(09)64008-8
M3 - Review article
C2 - 19903554
AN - SCOPUS:71549162528
SN - 0076-6879
VL - 464
SP - 147
EP - 166
JO - Methods in Enzymology
JF - Methods in Enzymology
IS - C
ER -
